TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentato dom 30 ago · 08:15 CESTHot Line 6Tutti gli studi Hot Line →

H-HeFT

2026

Hydralazine-ISDN in Patients With Chronic Heart Failure — Hydralazine Heart Failure Trial (H-HeFT), component of the DANish randomised, double-blind, placebo-controlled trial in patients with chronic HEART failure (DANHEART)

In 592 patients with HFrEF on guideline-directed therapy, hydralazine–isosorbide dinitrate did not reduce death or worsening heart failure compared with placebo.

Risultato

Efficacia: Time to first occurrence of the composite of death or hospitalisation with worsening heart failure (including an urgent visit requiring intravenous therapy or metolazone for heart failure, heart transplantation or LVAD implantation)HR 0,90 (IC 95% 0,67-1,21)

Sotto 1 a favore di hydralazine–isosorbide dinitrate, sopra 1 a favore di placebo.

Tassi di eventi Hydralazine–isosorbide dinitrate 8,6 vs placebo 9,3 per 100 anni-paziente

Riportato inoltre: Over follow-up up to 7 years: no significant difference. All-cause death 19.4% vs 24.2% (HR 0.72, 95% CI 0.51-1.02). Treatment discontinuation was high. A companion meta-analysis of 3 trials (A-HeFT, H-HeFT and one other, 2101 patients) showed lower all-cause death (HR 0.71, 0.58-0.87) and cardiovascular death (HR 0.65, 0.47-0.90), with inconsistent effects on heart failure hospitalisation.

Pubblicazione originale
Sottotema
Vasodilators
Disegno
investigator-initiated, multicentre (23 centres in Denmark), randomised 1:1, double-blind, placebo-controlled, event-driven; part of the 2 × 2 factorial DANHEART programme with Met-HeFT (patients may enter one or both substudies); hydralazine 37.5 mg/isosorbide dinitrate 20 mg twice daily, uptitrated, vs matching placebo; symptomatic chronic heart failure, LVEF ≤40%, systolic BP ≥100 mmHg, NT-proBNP >350 pg/mL or BNP >80 pg/mL; follow-up up to 7 years
Rilevanza
Importante: uno dei diversi pilastri.
Fonte
Køber L, et al. H-HeFT (DANHEART). Presented at ESC Congress 2026, Hot Line 6, 30 August 2026, Munich.doi 10.1093/eurheartj/ehag773

Discussione e critica

The first test of hydralazine-isosorbide dinitrate on top of four-pillar therapy, in a population defined by ejection fraction and natriuretic peptide rather than by race, and it was not powered for mortality. The mortality curves separate late and the intervals cross one; hospitalisations do not move at all, which is the harder finding to explain away for a vasodilator. Discontinuation was frequent enough that the investigators name tolerability as the practical limit: an old, cheap, six-tablets-a-day regimen has to be taken to work.